Fulcrum Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
FULC$3.720.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Loss | Deficit | Equity | |
| Balance at December 31, 2021 | 40,626,224 | 41 | 514,362 | (397) | (302,467) | 211,539 |
| Issuance of common stock in connection with public offering, net of issuance costs | 11,029,410 | 11 | 80,793 | — | — | 80,804 |
| Issuance of common stock under employee benefit plans | 433,403 | — | 3,519 | — | — | 3,519 |
| Vesting of restricted stock awards | 10,174 | — | 1 | — | — | 1 |
| Stock-based compensation expense | — | — | 13,350 | — | — | 13,350 |
| Unrealized loss on marketable securities | — | — | — | (400) | — | (400) |
| Net loss | — | — | — | — | (109,871) | (109,871) |
| Balance at December 31, 2022 | 52,099,211 | $52 | $612,025 | $(797) | $(412,338) | $198,942 |
| Issuance of common stock in connection with public offering, net of issuance costs | 9,615,384 | 10 | 117,336 | — | — | 117,346 |
| Issuance of common stock under employee benefit plans | 182,628 | — | 777 | — | — | 777 |
| Vesting of restricted stock awards | 18,144 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 14,802 | — | — | 14,802 |
| Unrealized gain on marketable securities | — | — | — | 661 | — | 661 |
| Net loss | — | — | — | — | (97,335) | (97,335) |
| Balance at December 31, 2023 | 61,915,367 | $62 | $744,940 | $(136) | $(509,673) | $235,193 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.